<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014712</url>
  </required_header>
  <id_info>
    <org_study_id>2018-4815</org_study_id>
    <nct_id>NCT04014712</nct_id>
  </id_info>
  <brief_title>O2 Transport and Utilization in Health and Lung Disease</brief_title>
  <official_title>Role of Nitric Oxide Coupling in Muscle Dysfunction With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Amherst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Amherst</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal muscle dysfunction is a frequent and clinically relevant systemic manifestation of&#xD;
      Chronic Pulmonary Obstructive Disease (COPD), which is still poorly understood. Therefore,&#xD;
      the focus of this study is on the role of a deficit in tetrahydrobiopterin and nitric oxide&#xD;
      synthase uncoupling induced by chronic oxidative stress on metabolic and vascular&#xD;
      abnormalities in skeletal muscle of patients suffering from COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the efficacy of supplementation with&#xD;
      tetrahydrobiopterin (BH4) for improving vascular and muscle function in patients with COPD&#xD;
      and healthy controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial function</measure>
    <time_frame>4 hours</time_frame>
    <description>PCr recovery kinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intracellular PO2</measure>
    <time_frame>4 hours</time_frame>
    <description>Myoglobin oxygenation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>systemic blood markers of oxidative stress</measure>
    <time_frame>4 hours</time_frame>
    <description>blood markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood flow</measure>
    <time_frame>4 hours</time_frame>
    <description>Exercise Blood flow by Doppler Ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COPD</condition>
  <condition>Tetrahydrobiopterin Deficiency</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>acute BH4/Tetrahydrobiopterin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement, Pill, 10 mg/kg of body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral supplement, Pill, Placebo pill with inert excipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrobiopterin</intervention_name>
    <description>Oral, Single dose</description>
    <arm_group_label>acute BH4/Tetrahydrobiopterin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects must be between the age of 18 and 85 years;&#xD;
&#xD;
          -  For the COPD cohort, patients with a diagnosis of stable COPD (i.e., those not&#xD;
             experiencing an acute exacerbation of symptoms) and spirometric evidence of airway&#xD;
             obstruction (FEV1 &lt;80% predicted, FEV/FVC&lt;0.70);&#xD;
&#xD;
          -  Ability to perform motor tests;&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled hypertension;&#xD;
&#xD;
          -  hyperlipidemia;&#xD;
&#xD;
          -  recent exacerbation;&#xD;
&#xD;
          -  Major cardiovascular event procedure (&lt;3 months);&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  known significant hepatic, renal disease, active substance abuse&#xD;
&#xD;
          -  contraindication to MRI, claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Applied Life Sciences</name>
      <address>
        <city>Amherst</city>
        <state>Massachusetts</state>
        <zip>01003</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gwenael Layec, PhD</last_name>
      <phone>413-345-2739</phone>
      <email>glayec@umass.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Emma Searles</last_name>
      <email>msearles@umass.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BH4</keyword>
  <keyword>Exercise</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months post-publication</ipd_time_frame>
    <ipd_access_criteria>Within 6 months after the data have been published, and upon written request, a limited, de-identified, anonymized dataset will be created pursuant to the Data use Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

